Adcetris or brentuximab vedotin

Learn about your cancer drugs.

New ’biologic’ drug made by Seatle Genetics. This targets lymphoma and costs roughly 9,000 pounds or $16,000 US a month. The mean increased survival time in research was 7 months. 

The FDA has approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an antibody - an antibody-drug conjugate - the antibody directs the drug to CD30, a target on lymphoma cells.

Adectris was approved under the FDA’s accelerated approval programme. However

the FDA approved Adcetris after evaluating a single-arm clinical trial with only 102 participants. Patients received only Adcetris. The human study’s endpoint was objective response rate - what percentage of participants’ tumours either shrank or disappeared altogether after treatment. 73% of them achieved either a partial or complete response, and responded to therapy for 6.7 months (average).

The systemic ALCL single-arm clinical trial involved only 58 patients. They received only Adcetris. The primary endpoint was the same; Objective response rate. 86% of them achieved either a partial or complete response, and responded for 12.6 months (average).

Side effects seem the usual nausea, fatigue, white cell decline, upper respiratory infection and sickness.
Learn about your cancer drugs.
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our

Join Our Newsletter Signup today for free and be the first to get notified on new updates.